Global Antidepressant Drugs Market Forecast up to 2024

  • 104
    Pages

  • 14
    Tables

  • 65
    Charts

  • 4 / 0
    Regions/ Countries

  • 12
    Companies

  • 10
    Enquiry Hours

[104 Report Pages] This market research report identifies Novartis AG, Allergan Inc., Elli Lilly and Company, AstraZeneca Plc, GSK, Otsuka Holdings Co., Ltd., and Johnson & Johnson as the major vendors operating in the global antidepressant drugs market. This report also provides a detailed analysis of the market by drug class (SSRI, NDRI, SNRI, MAOI, TCA and Others) and region (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Antidepressant Drugs market

Infoholic’s market research report predicts that the global antidepressant drugs market will grow at a CAGR of 2.2% during the forecast period 2018–2024.  The major drivers of the market are the growing aging population and increasing prevalence of depression which are driving the global antidepressant drugs market growth. Supportive initiatives from the government and other organizations and increasing clinical trials will provide an opportunity for the market growth of the antidepressant drugs market in the future.

According to the antidepressant drugs market analysis, North America accounts for the largest share of the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 30% of the market, with a significant contribution from the US to the market growth.

Competitive Analysis and Key Vendors

At the global level, over 300 million people are estimated to suffer from depression, which is equivalent to 4.4% of the world’s total population. Only less than 10% of the affected people are treated although there is the availability of branded and effective treatments for depression. The challenges for effective care include lack of capitals, unavailability of qualified healthcare providers, and public stigma associated with mental disorders. Along with these, imprecise assessment of the condition is also a challenge which is faced globally.

Government initiatives have been greatly changing the antidepressant drugs market scenario. Many initiatives are taken to increase the awareness and reduce the suicidal rate globally. Depression is confined by the mental health Gap Action Programme (mhGAP) of the World Health Organization (WHO) to assists countries to increase their facilities for those suffering from mental disorders, through special aid by healthcare workers. A special transitory was established by WHO for the treatment of depression. The companies are striving to develop innovative drugs to address the unmet needs in the market. For instance, in May 2018, Esketamine Nasal Spray of Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated rapid enhancements in depressive symptoms in patients with treatment-resistant depression in phase III trials. Thus, this drug is expected to be one of the bestsellers in the market.

Some of the Antidepressant Drugs Market key vendors:

  • Novartis AG
  • Allergan Inc
  • Elli Lilly and Company
  • AstraZeneca Plc
  • GSK
  • Otsuka Holdings Co., Ltd
  • Johnson and Johnson

The other prominent players include Pfizer, Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd., and H. Lundbeck A/S.

Antidepressant Drugs Market by Drug Class

  • Selective serotonin reuptake inhibitors (SSRIs)
  • Norepinephrine-dopamine reuptake inhibitor (NDRI)
  • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Monoamine oxidase inhibitors (MAOIs)
  • Tricyclic antidepressants (TCAs)
  • Others

During the forecast period, SSRIs are the most attractive drug in the market, owing to the highly effective treatment of depression and anxiety.

Benefits

The report provides detailed information about the usage and adoption of antidepressant drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the product adoption during the forecast period in the market. Moreover, the report provides details about the major challenges that are going to have an impact on market growth. Additionally, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture revenues in the specific verticals. The report will help companies interested or established in this market to analyze the various aspects of this domain before investing or expanding their business in the antidepressant drugs market.

Key Stakeholders:

antidepressant-drugs

1. Industry Outlook

1.1        Industry Overview

1.2        Industry Trends

1.3        Total Addressable Market

2.  Report Outline

2.1        Report Scope

2.2        Report Summary

2.3        Research Methodology

2.4        Report Assumptions

3.  Market Snapshot

3.1        Market Definition – Infoholic Research

3.2        Segmented Addressable Market

3.2.1     Trends in the Antidepressant Drugs Market

3.3        Related Markets

3.3.1     Neurosurgical Devices

3.3.2     Parkinson Drugs

3.3.2.1    Trends of Parkinson Diseases Market

3.3.3     Neurointerventional Devices

3.3.4     Over the Counter Drugs (OTC)

4.  Market Outline

4.1        Antidepressant Drugs Pipeline

4.2        Market Segmentation

4.3        Porter 5(Five) Forces

4.4        PEST Analysis

5.  Market Characteristics

5.1        Market Dynamics

5.1.1     Drivers

5.1.1.1    Increasing aging population

5.1.1.2    Increasing prevalence of Depression

5.1.2     Opportunities

5.1.2.1    Government Initiatives

5.1.2.2    Exhaustive Pipeline and Increasing Clinical Trials

5.1.3     Restraints

5.1.3.1    Complex drug development process

5.1.3.2    Adverse effects of antidepressant drugs

5.2        DRO – Impact Analysis

5.3        Key Stakeholders

6.  Drug Class: Market Size and Analysis

6.1        Overview

6.2        Selective serotonin reuptake inhibitors (SSRIs)

6.3        Norepinephrine-dopamine reuptake inhibitor (NDRI)

6.4        Serotonin and norepinephrine reuptake inhibitors (SNRIs)

6.5        Monoamine oxidase inhibitors (MAOIs)

6.6        Tricyclic antidepressants (TCAs)

6.7        Others

7.  Regions: Market Size and Analysis

7.1        Overview

7.2        North America

7.2.1     Overview

7.3        Europe

7.3.1     Overview

7.4        Asia Pacific

7.4.1     Overview

7.5        Rest of the World

7.5.1     Overview

8.  Competitive Landscape

9.  Vendor Profiles

9.1        AstraZeneca PLC

9.1.1     Overview

9.1.2     Business Units

9.1.3     Geographic Presence

9.1.4     Business Focus

9.1.5     SWOT Analysis

9.1.6     Business Strategies

9.2        Eli Lilly & Company Ltd.

9.2.1     Overview

9.2.2     Business Units

9.2.3     Geographic Revenue

9.2.4     Business Focus

9.2.5     SWOT Analysis

9.2.6     Business Strategies

9.3        GlaxoSmithKline plc

9.3.1     Overview

9.3.2     Business Units

9.3.3     Geographic Presence

9.3.4     Business Focus

9.3.5     SWOT Analysis

9.3.6     Business Strategies

9.4        Johnson & Johnson

9.4.1     Overview

9.4.2     Business Units

9.4.3     Geographic Revenue

9.4.4     Business Focus

9.4.5     SWOT Analysis

9.4.6     Business Strategies

9.5        Novartis AG

9.5.1     Overview

9.5.2     Business Units

9.5.3     Geographic Presence

9.5.4     Business Focus

9.5.5     SWOT Analysis

9.5.6     Business Strategy

9.6        Otsuka Holdings Co., Ltd.

9.6.1     Overview

9.6.2     Business Units

9.6.3     Geographic Revenue

9.6.4     Business Focus

9.6.5     SWOT Analysis

9.6.6     Business Strategies

9.7        Allergan PLC

9.7.1     Overview

9.7.2     Business Units

9.7.3     Geographic Revenue

9.7.4     Business Focus

9.7.5     SWOT Analysis

9.7.6     Business Strategies

10.  Companies to Watch for

10.1     Pfizer, Inc.

10.1.1  Overview

10.1.2  Highlights

10.2     Takeda Pharmaceutical Co. Ltd.

10.2.1  Overview

10.2.2  Highlights

10.3     Shionogi & Co. Ltd.

10.3.1  Overview

10.3.2  Highlights

10.4     Abbott Laboratories

10.4.1  Overview

10.5     H. Lundbeck A/S

10.5.1  Overview

Annexure

Abbreviations

Infoholic research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting

infoholic Research Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.